New antibody combo takes on advanced cancers in first human trial
NCT ID NCT04130542
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested an experimental drug called LVGN6051, which activates immune cells by targeting CD137, both alone and combined with the approved immunotherapy Keytruda. The study involved 105 adults with advanced or metastatic cancers that had spread. The main goal was to find a safe dose and check for side effects, not yet to measure how well it fights cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LVGN6051 (an experimental antibody) and pembrolizumab (Keytruda, an approved immunotherapy)
- What this could lead to
- If successful, this could lead to a new treatment option for people with advanced cancers that have not responded to other therapies.
- What could go wrong
- This is a very early (Phase 1) trial focused on safety and dosing, not on proving effectiveness. Many experimental cancer drugs fail in later stages. Side effects from immune activation could be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC MALIGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030-3722, United States
-
NYU Langone Health
New York, New York, 10016, United States
-
Nebraska Cancer Specialist
Omaha, Nebraska, 68130, United States
-
The Johns Hopkins University
Baltimore, Maryland, 21205, United States
-
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94115, United States
-
University of California Irvine Health
Orange, California, 92868, United States
-
Verdi Oncology Research
Lafayette, Indiana, 47905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Could sitting up make radiation therapy more comfortable?
- Can we predict dangerous side effects when combining radiation and immunotherapy?
- Family history as a shield: can culturally tailored guidance cut cancer risk?
- A simple screening program could transform cancer aftercare
- Can simple positive activities boost Well-Being in cancer care?